AstraZeneca Halts Phase III Lung Cancer Trial as Drug Falls Short Against Keytruda — BigGo Finance
AstraZeneca has terminated a late-stage clinical trial for its experimental bispecific antibody volrustomig in metastatic non-small cell lung…
AstraZeneca reports Phase III results for Ultomiris and Sone-Ve
AstraZeneca has released findings from two Phase III studies of Ultomiris (ravulizumab) in thrombotic microangiopathy following haematopoietic stem…
AstraZeneca reports Phase III results for Ultomiris and Sone-Ve
AstraZeneca has released findings from two Phase III studies of Ultomiris (ravulizumab) in thrombotic microangiopathy following haematopoietic stem…
AstraZeneca reports first-half growth, disappointment in Ultomiris trial
AstraZeneca reported first-half total revenue of $30.7bn on Monday, up 9%, while core earnings per share increased 12%…
AstraZeneca updates Ultomiris HSCT-TMA Phase III data | AZN SEC Filing
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant…
FDA Accepts AstraZeneca’s Filing for Expanded Use of Ultomiris
AstraZeneca AZN announced that the FDA has accepted a regulatory filing seeking to expand the use of its blockbuster…
FDA Grants Priority Review to AstraZeneca’s Ultomiris for Rare Kidney Disease Treatment (AZN)
medical research woman microscope NEW SIZE ©Adobe Stock Images AstraZeneca’s (LSE:AZN) rare disease division, Alexion, has received a…
AstraZeneca reports major Phase III breakthrough in IgA kidney disease trial
AstraZeneca says its drug Ultomiris has delivered a statistically significant reduction in proteinuria in adults with immunoglobulin A…